Treatment of classical Hodgkin lymphoma in young adults aged 18–30 years with a modified paediatric Hodgkin lymphoma protocol. Results of a multicentre phase II clinical trial (CRUK/08/012)
Open Access
- 11 November 2019
- journal article
- research article
- Published by Wiley in British Journal of Haematology
- Vol. 189 (1) , 128-132
Abstract
Summary: This phase II trial was designed to determine the safety and efficacy of a modified paediatric risk‐stratified protocol in young adults (18–30 years) with classical Hodgkin Lymphoma. The primary end‐point was neurotoxicity rate. The incidence of grade 3 neurotoxicity was 11% (80% CI, 5–19%); a true rate of neuropathy of >15% cannot be excluded. Neuropathy and associated deterioration in quality of life was largely reversible. The overall response rate was 100% with 40% complete remission (CR) rate. Twelve months disease‐free survival (DFS) was 91%. We demonstrate that a risk‐stratified paediatric combined modality treatment approach can be delivered to young adults without significant irreversible neuropathy.Keywords
Funding Information
- Cancer Research UK (C13431/A8315)
This publication has 14 references indexed in Scilit:
- Adapted Treatment Guided by Interim PET-CT Scan in Advanced Hodgkin’s LymphomaNew England Journal of Medicine, 2016
- Resolutions for the New YearHaematologica, 2015
- Results of a Trial of PET-Directed Therapy for Early-Stage Hodgkin’s LymphomaNew England Journal of Medicine, 2015
- Recommendations for Initial Evaluation, Staging, and Response Assessment of Hodgkin and Non-Hodgkin Lymphoma: The Lugano ClassificationJournal of Clinical Oncology, 2014
- Treatment of Children and Adolescents With Hodgkin Lymphoma Without Radiotherapy for Patients in Complete Remission After Chemotherapy: Final Results of the Multinational Trial GPOH-HD95Journal of Clinical Oncology, 2013
- Reduced-intensity chemotherapy and PET-guided radiotherapy in patients with advanced stage Hodgkin's lymphoma (HD15 trial): a randomised, open-label, phase 3 non-inferiority trialThe Lancet, 2012
- Two escalated followed by six standard BEACOPP in advanced-stage high-risk classical Hodgkin lymphoma: high cure rates but increased risk of aseptic osteonecrosisAnnals of Oncology, 2011
- Procarbazine-Free OEPA-COPDAC Chemotherapy in Boys and Standard OPPA-COPP in Girls Have Comparable Effectiveness in Pediatric Hodgkin's Lymphoma: The GPOH-HD-2002 StudyJournal of Clinical Oncology, 2010
- Revised Response Criteria for Malignant LymphomaJournal of Clinical Oncology, 2007
- Standard and Increased-Dose BEACOPP Chemotherapy Compared with COPP-ABVD for Advanced Hodgkin's DiseaseNew England Journal of Medicine, 2003